SYRE Q1 2019 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$18M

Net Income

-$17M

EPS (Diluted)

$-14.79

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$129M

Total Liabilities

$12M

Stockholders' Equity

$116M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$2M	-100.0%
Gross Profit	$0	$0	—
Operating Income	-$18M	-$8M	-114.2%
Net Income	-$17M	-$8M	-111.4%